Type 2 diabetes patients with polyvascular disease at increased risk of MACE: EXSCEL trial

USA: The risk of MACE and mortality increases incrementally with each additional diseased arterial bed in patients with type 2 diabetes versus those without atherosclerotic vascular disease, show results from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. The study was published in the journal Atherosclerosis on November 01, 2021.

Polyvascular disease is known to be an independent predictor of major adverse cardiovascular events (MACE) and all-cause mortality (ACM). The relationship between the number of diseased arterial beds and MACE, especially in type 2 diabetes (T2D) patients, is not known. Also, it is unknown of r heart failure (HF) status and hemoglobin A1c (HbA1c) levels influence outcomes in polyvascular disease.

Against the above background, Marc D. Samsky, Duke University School of Medicine, Durham, NC, USA, and colleagues' analysis from the EXSCEL trial was aimed to examine the risk associated with an increasing number of diseased arterial beds on MACE and ACM. 

Cox models were used to test associations between the number of diseased arterial beds and MACE and ACM. The researchers also performed prespecified interaction testing between the number of diseased arterial beds with baseline HF, HbA1c (≤8% vs. >8%), and treatment assignment. 

The researchers concluded, "In patients with T2D, compared to those without atherosclerotic vascular disease, risk of MACE and ACM increases incrementally with each additional diseased arterial bed."

Reference:

The study titled, "Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial," is published in the journal Atherosclerosis.

DOI: https://www.atherosclerosis-journal.com/article/S0021-9150(21)01409-X/fulltext